ArticleCell biochemistry and biophysics2026
Alpha-Lipoic Acid Attenuates Fibrotic and Inflammatory Dermal Remodelling in a Bleomycin-Induced Skin Model.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bleomycin (BLM) is a widely used chemotherapeutic agent associated with cutaneous toxicity characterised by inflammation, oxidative stress, and progressive fibrosis. However, effective strategies to mitigate these adverse tissue responses remain limited. This study aimed to evaluate potential protective effects of alpha-lipoic acid (ALA) against the BLM-induced skin model, focusing on fibrotic, inflammatory, and proliferative alterations. Thirty adult Wistar albino rats were randomly assigned to four groups: Control, ALA, BLM, and BLM + ALA. BLM (30 mg/m²) was administered intramuscularly on Days 1, 8, and 15, whereas ALA (50 mg/kg/day, subcutaneously) was administered once daily from Days 1-14. Skin tissues were collected immediately after the final scheduled treatment on Day 15 for histopathological and immunohistochemical analyses. Histopathological evaluation was performed using H&E, Masson's trichrome, and Toluidine blue staining. Immunohistochemical staining was conducted to evaluate the expression levels of collagen types I and III, interleukin-6 (IL-6), inducible nitric oxide synthase (iNOS), caspase-1, and the proliferation marker Ki-67, followed by quantitative image analysis. BLM exposure resulted in marked epidermal thickening, inflammatory cell infiltration, increased collagen deposition, and elevated mast cell density compared with controls. These histopathological alterations were significantly attenuated in the BLM + ALA group. Consistently, BLM significantly increased the expression of collagen I/III, IL-6, iNOS, caspase-1, and Ki-67, whereas ALA treatment significantly reduced these elevations. Overall, ALA attenuated BLM-induced dermal alterations. ALA treatment was associated with reduced collagen deposition and decreased IL-6, iNOS, caspase-1, and Ki-67 immunoreactivity in the experimental skin model. Further mechanistic studies are required to establish the causal relationships underlying these observations.
Indexed as
Identifiers
42709395What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.